A Partially Randomized, Partly Placebo Controlled Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA-BN RSV Vaccine After Intranasal and Intramuscular Administration
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2017
At a glance
- Drugs MVA-BN RSV (Primary) ; MVA-BN RSV (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- 20 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2019.
- 20 Jul 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Aug 2019.
- 20 Jul 2017 Planned initiation date changed from 1 Sep 2016 to 1 Sep 2018.